Solid Biosciences (SLDB) Competitors

Solid Biosciences (NASDAQ:SLDB) and 89bio (NASDAQ:ETNB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

Do institutionals and insiders believe in SLDB or ETNB?

81.5% of Solid Biosciences shares are held by institutional investors. 13.6% of Solid Biosciences shares are held by insiders. Comparatively, 2.8% of 89bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Which has more volatility & risk, SLDB or ETNB?

Solid Biosciences has a beta of 2.07, suggesting that its share price is 107% more volatile than the S&P 500. Comparatively, 89bio has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500.

Does the media favor SLDB or ETNB?

In the previous week, Solid Biosciences and Solid Biosciences both had 9 articles in the media. 89bio's average media sentiment score of 1.06 beat Solid Biosciences' score of 0.95 indicating that 89bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
89bio	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor SLDB or ETNB?

Solid Biosciences received 160 more outperform votes than 89bio when rated by MarketBeat users. Likewise, 69.27% of users gave Solid Biosciences an outperform vote while only 62.84% of users gave 89bio an outperform vote.

Company	Underperform	Outperform
Solid Biosciences	Outperform Votes 275 69.27%	Underperform Votes 122 30.73%
89bio	Outperform Votes 115 62.84%	Underperform Votes 68 37.16%

Do analysts rate SLDB or ETNB?

Solid Biosciences currently has a consensus target price of $15.67, indicating a potential upside of 373.31%. 89bio has a consensus target price of $27.25, indicating a potential upside of 239.78%. Given Solid Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Solid Biosciences is more favorable than 89bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	4 Strong Buy rating(s)	3.33
89bio	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

Is SLDB or ETNB more profitable?

Solid Biosciences' return on equity of -58.75% beat 89bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-58.75%	-47.84%
89bio	N/A	-59.58%	-52.21%

Which has preferable earnings & valuation, SLDB or ETNB?

Solid Biosciences has higher revenue and earnings than 89bio. 89bio is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	$8.09M	31.71	-$96.01M	-$3.04	-1.09
89bio	N/A	N/A	-$142.19M	-$3.43	-2.34

Summary

Solid Biosciences beats 89bio on 15 of the 16 factors compared between the two stocks.